A magnetic particle separation system includes a magnetic field generating device having an upper surface with a receiving area formed thereon; and a magnetic field generating element disposed beneath the upper surface, the magnetic field generating element being configured to produce a magnetic field above the upper surface. A container assembly is disposed on the upper surface and includes: a flexible container having an outer wall with an interior surface that at least partially bounds an internal compartment, the outer wall having a front side and an opposing back side with the internal compartment disposed therebetween; a fluid inlet extending through the outer wall at the front side; a fluid outlet extending through the outer wall at the front side; and a first partition projecting into the internal compartment from the front side between the fluid inlet and the fluid outlet.

A blood analysis system for analysis and correction of blood of a subject includes a centrifugation unit to receive blood of a subject. The centrifugation unit is configured to hold capturing molecules for chemical capture of molecules and/or ions that deactivate at least one of coagulation and complement pathways in the blood and centrifuge to suspend cellular components with a minimal plasma along with the capturing molecules. The blood analysis system includes a correction unit coupled to the centrifugation unit to receive the minimal plasma having the capturing molecules and the cellular components from the centrifugation unit. The correction unit is configured to extract the capturing molecules from the minimal plasma, prior to infusing the minimal plasma having the cellular components along with replaced captured molecules and/or ions back to the subject and discarding the extracted capturing molecules.

The invention concerns devices and methods of filtering metallic nanoparticles and thrombi or microthrombi and other undesirable particles or molecules from blood or blood products.

The present disclosure relates to a device for removing undesired matter, pathogens, and toxins from a fluid and human blood.

Devices for monitoring cancerous cells in blood of a patient that are preloaded with a marker and a magnetic agent and removing them are provided. The device comprises a tray onto which blood withdrawn from the patient flows before returned to the patient; a magnet placed at a distance from the tray so that the blood on the tray is within a magnetic field of the magnet and the cancerous cells that are preloaded with the magnetic agent are forced to move from the blood on the tray towards the magnet. A detector configured to detect the marker in the cancerous cells in the blood on the tray is provided as well and a filter that is placed between the tray and the magnet so as to capture the cancerous cells that are forced to move towards the magnet and remove them from the blood of the patient.

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder, a pump and a plurality of valves configured to at least partially control fluid flow through a fluid circuitry and a separation column positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

The present disclosure provides a method of removing a target substance from blood of a patient, the method comprising steps of: providing a complexing agent, especially a supra-molecular compound or core particle, adapted for selectively binding a target molecule or target entity in the blood of the patient in a complex, e.g. a supra-molecular complex; administering the complexing agent into the patient's blood, preferably into an extracorporeal blood flow pathway, for binding with the target molecule or the target entity; conveying the blood having the complexing agent through a treatment zone of an extracorporeal blood flow pathway for a predetermined period of time to bind or incorporate the target molecule or target entity within the blood in a complex, such as a supra-molecular complex; and removing the complex (e.g. supra-molecular complex) from the blood by haemodialysis, which preferably includes one or more of filtration, ultrafiltration, convection, or adsorption. The disclosure thus also provides a system (1) for removing a target substance from blood of a patient, the system (1) comprising: an extracorporeal blood flow pathway (2) for connection to a patient and for guiding or conveying a flow of blood from the patient along the pathway; a treatment zone (5) arranged in the extracorporeal blood flow pathway (2) for mixing a complexing agent (C) with the blood adapted to bind a target molecule (M) in a complex (X), especially a supra-molecular complex or core particle complex, as the blood flows through the treatment zone (5); and a haemodialysis unit (4) for separating the complex (X) from the blood via one or more of filtration, ultra-filtration, convection, and membrane adsorption, with or without magnetic assistance.

The present invention in some embodiments thereof relates to an apheresis device for collecting and/or removing substances from the blood, such as, circulating tumor cells (CTCs), selected proteins, lipids, pathogens, various harmful substances, etc. More particularly, but not exclusively, the device may be used to reduce the amount of CTCs and/or for personalized immunotherapy.

This system for recovering an antigen in a solvent includes charged particles, a mixing unit, and a recovery unit, wherein: the charged particles each contain 3-70 mol % of a cationic lipid, 1-20 mol % of a PEG-containing lipid, and 20-50 mol % of cholesterol; the surfaces of the charged particles are modified with antibodies; the average zeta potential of the charged particles is 20 to +15 mV; the mixing unit is configured such that the charged particles are added to a solvent and the charged particles and the solvent are stirred in the mixing unit; the recovery unit 7 is configured to recover the charged particles mixed with the solvent; and the recovery unit is an anionic adsorber that includes an adsorption carrier having a surface on which a compound having an anionic functional group is immobilized.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.